Chris Ryan

The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.

Outpatient lymphodepletion before brexucabtagene autoleucel was safe and showed similar non-relapse mortality compared with inpatient administration in B-ALL and MCL.

Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer, according to data from an interim analysis of the phase 3 POLESTAR trial.

The application is supported by results from the phase III DESTINY-Breast06 trial.

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, offering a promising approach to deeper disease response.

TORL-1-23 was well tolerated and showed efficacy in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to improvements in overall survival among patients with triple-negative breast cancer.

Valemetostat showed promise as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma.

Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.

Fianlimab plus cemiplimab was well-tolerated and showed durable responses, in pretreated patients with advanced clear cell renal carcinoma.

Zanubrutinib treatment resulted in £599,000 cost savings and 3.7 QALY savings compared with acalabrutinib for 1000 hypothetical patients.

A daratumumab-VRd–based regimen boosted the rate of MRD-negativity in patients with newly diagnosed, transplant-eligible multiple myeloma.

Trastuzumab deruxtecan therapy led to superior PFS vs chemotherapy in pretreated, HR-positive, HER2-low metastatic breast cancer as well as ‘ultralow’ disease with IHC 0 and membrane staining.

Osimertinib given after chemoradiation in patients with advanced non–small cell lung cancer harboring a EGFR mutation showed significant benefits.

Combining encorafenib/binimetinib before nivolumab/ipilimumab did not improve progression-free survival in BRAF V600E/K+ metastatic melanoma.

According to findings from a retrospective analysis, young adults under 40 years of age who received a human papillomavirus vaccination had lower rates of HPV-related cancer.

TNO155 combined with either spartalizumab or ribociclib showed acceptable safety and tolerability across solid tumors in a phase 1b open-label study.

Rates of cervical cancer across the United States vary due to social determinants of health.

In a presentation at the 2023 International Kidney Cancer Symposium, Maxine Sun, PhD, MPH, discussed the relationship between clonal hematopoiesis in patients with kidney cancer and their risk for cardiac events.

Data presented at the 2023 ESMO Congress and showed that induction chemotherapy followed by chemoradiation reduced the risk of progression or death by 35% vs chemoradiation alone in patients with cervical cancer.

Treatment with sacituzumab govitecan-hziy in the second line demonstrated responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

The Isa-KRd combination in the GMMG-CONCEPT trial yielded high MRD negativity rates among patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.

Pemigatinib showed antitumor activity in patients with cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.

Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Data presented at the ASCO 2023 Annual Meeting showed that the addition of pembrolizumab to pemetrexed and platinum-based chemotherapy did not statistically improve survival in patients with TKI-resistant EGFR-mutated non–small cell lung cancer.

According to Binod Dhakal, MD, ciltacabtagene autoleucel may become a new standard therapy for patients with lenalidomide (Revlimid)-refractory multiple myeloma.

Pooled findings from MagnetisMM studies show the elranatamab has early activity in relapsed or refractory multiple myeloma.

ADAURA is the first global phase 3 study to demonstrate statistically significant and clinically meaningful disease-free survival and overall survival benefit with adjuvant targeted therapy for patients with EGFR-mutated, stage IB to IIIA NSCLC.

New results from the phase 2 APPLE trial shows how the use of osimertinib in the upfront setting compares with combination therapy in patients with EGFR-positive non–small cell lung cancer.

Toripalimab with bevacizumab and platinum-based chemotherapy showed promising response and disease control rates in patients with refractory, recurrent and metastatic cervical cancer.